A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations

Key Inclusion Criteria: 1. Adult men and women between 18 to 75 years of age, inclusive, at time of consent with a diagnosis of inherited erythromelalgia with a previously characterized gain of function NaV1.7 mutation resulting in chronic pain. 2. Absence of concomitant mutation resulting in Kv7.2/7.3 gain of function. 3. Ability and willingness to adhere to the study procedures and complete accurate pain diaries 4. Stable background analgesic regimen for at least 30 days before screening and willingness to maintain the same analgesic regimen during the study period. Key Exclusion Criteria:…